Symbols / ACTU Stock $1.95 +1.04% Actuate Therapeutics, Inc. Common stock

Healthcare • Biotechnology • United States • NGM
ACTU (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Daniel M. Schmitt
Exch · Country NGM · United States
Market Cap 46.66M
Enterprise Value 38.52M
Income -21.54M
Sales —
FCF (ttm) -11.84M
Book/sh 0.16
Cash/sh 0.34
Employees 12
Insider 10d —
IPO Aug 13, 2024
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.29
PEG —
P/S —
P/B 12.19
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio 1.72
Current Ratio 1.80
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.98
EPS next Y -0.85
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-13
Earnings (prior) 2026-05-14
ROA -203.78%
ROE —
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 23.93M
Shs Float 8.57M
Insider Own 15.36%
Instit Own 58.16%
Short Float 8.79%
Short Ratio 7.55
Short Interest 920.63K
52W High 9.22
vs 52W High -78.85%
52W Low 1.58
vs 52W Low 23.42%
Beta —
Impl. Vol. —
Rel Volume 0.33
Avg Volume 164.25K
Volume 54.77K
Target (mean) $9.98
Tgt Median $10.00
Tgt Low $5.00
Tgt High $14.91
# Analysts 4
Recom Strong_buy
Prev Close $1.93
Price $1.95
Change 1.04%
About

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.98
Mean price target
2. Current target
$1.95
Latest analyst target
3. DCF / Fair value
$-8.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.95
Low
$5.00
High
$14.91
Mean
$9.98

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-18 reit HC Wainwright & Co. Buy → Buy $15
2026-04-22 reit HC Wainwright & Co. Buy → Buy $15
2026-04-13 main HC Wainwright & Co. Buy → Buy $15
2025-11-19 reit HC Wainwright & Co. Buy → Buy $20
2025-09-23 reit HC Wainwright & Co. Buy → Buy $20
2025-08-26 init B. Riley Securities — → Buy $20
2025-08-18 reit HC Wainwright & Co. Buy → Buy $20
2025-03-17 init HC Wainwright & Co. — → Buy $20
News
RSS: Latest ACTU news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-13 SCHMITT DANIEL M. Chief Executive Officer — 272,055 — —
2026-01-05 THOMSON TODD S. Director and Beneficial Owner of more than 10% of a Class of Security — 280,000 $5.80 $1,624,000
2025-06-27 BIOS EQUITY COF, LP Beneficial Owner of more than 10% of a Class of Security — 71,428 $7.00 $499,996
2024-08-14 THOMSON TODD S. Director and Beneficial Owner of more than 10% of a Class of Security — 18,750 $8.00 $150,000
2024-08-14 THOMSON TODD S. Director and Beneficial Owner of more than 10% of a Class of Security — 2,605,776 — —
2024-08-14 BIOS EQUITY COF, LP Beneficial Owner of more than 10% of a Class of Security — 500,000 $8.00 $4,000,000
2024-08-14 BIOS EQUITY COF, LP Beneficial Owner of more than 10% of a Class of Security — 24,999 $8.00 $199,992
2024-08-14 BIOS EQUITY COF, LP Beneficial Owner of more than 10% of a Class of Security — 9,418,650 $5.27 $200,002
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
22.50
-10.59%
25.16
+0.75%
24.97
+23.59%
20.21
Research And Development
10.29
-44.89%
18.68
-13.97%
21.71
+32.47%
16.39
Selling General And Administration
12.20
+88.18%
6.48
+98.57%
3.27
-14.51%
3.82
General And Administrative Expense
12.20
+88.18%
6.48
+98.57%
3.27
-14.51%
3.82
Salaries And Wages
7.61
+101.68%
3.77
+106.37%
1.83
-29.15%
2.58
Other Gand A
4.60
+69.43%
2.71
+88.67%
1.44
+15.95%
1.24
Total Expenses
22.50
-10.59%
25.16
+0.75%
24.97
+23.59%
20.21
Operating Income
-22.50
+10.59%
-25.16
-0.75%
-24.97
-23.59%
-20.21
Total Operating Income As Reported
-22.50
+10.59%
-25.16
-0.75%
-24.97
-23.59%
-20.21
EBITDA
-22.21
+18.55%
-27.27
-10.39%
-24.70
-22.63%
-20.14
Normalized EBITDA
-22.21
+19.34%
-27.53
-11.82%
-24.62
-22.01%
-20.18
EBIT
-22.21
+18.55%
-27.27
-10.39%
-24.70
-22.63%
-20.14
Total Unusual Items
—
0.26
+431.16%
-0.08
-318.22%
0.04
Total Unusual Items Excluding Goodwill
—
0.26
+431.16%
-0.08
-318.22%
0.04
Net Income
-22.23
+18.54%
-27.29
-10.27%
-24.74
-22.74%
-20.16
Pretax Income
-22.23
+18.54%
-27.29
-10.27%
-24.74
-22.74%
-20.16
Net Non Operating Interest Income Expense
0.27
+31.38%
0.20
-34.12%
0.31
+2754.26%
0.01
Interest Expense Non Operating
0.02
+8.19%
0.02
-57.11%
0.04
+169.39%
0.02
Net Interest Income
0.27
+31.38%
0.20
-34.12%
0.31
+2754.26%
0.01
Interest Expense
0.02
+8.19%
0.02
-57.11%
0.04
+169.39%
0.02
Interest Income Non Operating
0.29
+29.43%
0.22
-36.97%
0.35
+1204.89%
0.03
Interest Income
0.29
+29.43%
0.22
-36.97%
0.35
+1204.89%
0.03
Other Income Expense
—
-2.33
-2816.70%
-0.08
-318.22%
0.04
Other Non Operating Income Expenses
—
-2.59
—
—
Gain On Sale Of Security
—
0.26
+431.16%
-0.08
-318.22%
0.04
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-22.23
+18.54%
-27.29
-10.27%
-24.74
-22.74%
-20.16
Net Income From Continuing Operation Net Minority Interest
-22.23
+18.54%
-27.29
-10.27%
-24.74
-22.74%
-20.16
Net Income From Continuing And Discontinued Operation
-22.23
+18.54%
-27.29
-10.27%
-24.74
-22.74%
-20.16
Net Income Continuous Operations
-22.23
+18.54%
-27.29
-10.27%
-24.74
-22.74%
-20.16
Normalized Income
-22.23
+19.32%
-27.55
-11.70%
-24.66
-22.13%
-20.20
Net Income Common Stockholders
-22.23
+18.54%
-27.29
-10.27%
-24.74
-22.74%
-20.16
Diluted EPS
-1.06
+67.48%
-3.26
-151.79%
-1.29
+3.45%
-1.34
Basic EPS
-1.06
+67.48%
-3.26
-151.79%
-1.29
+3.45%
-1.34
Basic Average Shares
21.02
+151.07%
8.37
-56.19%
19.11
+27.13%
15.03
Diluted Average Shares
21.02
+151.07%
8.37
-56.19%
19.11
+27.13%
15.03
Diluted NI Availto Com Stockholders
-22.23
+18.54%
-27.29
-10.27%
-24.74
-22.74%
-20.16
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
14.04
+50.62%
9.32
+211.07%
3.00
-85.38%
20.48
Current Assets
13.64
+48.17%
9.21
+207.38%
3.00
-85.38%
20.48
Cash Cash Equivalents And Short Term Investments
13.16
+52.28%
8.64
+192.08%
2.96
-85.53%
20.45
Cash And Cash Equivalents
13.16
+52.28%
8.64
+192.08%
2.96
-85.53%
20.45
Other Current Assets
0.48
-14.53%
0.57
+1434.34%
0.04
+9.37%
0.03
Total Non Current Assets
0.39
+255.04%
0.11
0.00
0.00
Other Non Current Assets
0.39
+255.04%
0.11
—
—
Total Liabilities Net Minority Interest
6.11
-33.67%
9.21
-91.02%
102.62
+7.13%
95.79
Current Liabilities
5.71
-35.17%
8.80
+27.19%
6.92
+59.28%
4.34
Payables And Accrued Expenses
5.12
-35.32%
7.91
+19.13%
6.64
+57.68%
4.21
Payables
1.52
-20.66%
1.92
-43.86%
3.42
+60.59%
2.13
Accounts Payable
1.52
-20.66%
1.92
-43.86%
3.42
+60.59%
2.13
Current Accrued Expenses
3.59
-40.02%
5.99
+86.04%
3.22
+54.71%
2.08
Pensionand Other Post Retirement Benefit Plans Current
0.59
-33.78%
0.89
+220.16%
0.28
+110.17%
0.13
Total Non Current Liabilities Net Minority Interest
0.40
-1.64%
0.41
-99.57%
95.70
+4.66%
91.44
Tradeand Other Payables Non Current
0.40
+0.00%
0.40
+0.00%
0.40
+0.00%
0.40
Preferred Securities Outside Stock Equity
—
0.00
-100.00%
94.18
+4.48%
90.14
Stockholders Equity
7.92
+7505.63%
0.10
+100.10%
-99.63
-32.30%
-75.31
Common Stock Equity
7.92
+7505.63%
0.10
+100.10%
-99.63
-32.30%
-75.31
Capital Stock
0.00
+15.00%
0.00
+900.00%
0.00
+0.00%
0.00
Common Stock
0.00
+15.00%
0.00
+900.00%
0.00
+0.00%
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
23.25
+19.01%
19.53
+2.20%
19.11
+0.00%
19.11
Ordinary Shares Number
23.25
+19.01%
19.53
+2.20%
19.11
+0.00%
19.11
Additional Paid In Capital
162.53
+22.68%
132.48
+2322.89%
5.47
+8.40%
5.04
Retained Earnings
-154.61
-16.79%
-132.38
-25.96%
-105.09
-30.80%
-80.35
Total Equity Gross Minority Interest
7.92
+7505.63%
0.10
+100.10%
-99.63
-32.30%
-75.31
Total Capitalization
7.92
+7505.63%
0.10
+100.10%
-99.63
-32.30%
-75.31
Working Capital
7.94
+1857.71%
0.41
+110.33%
-3.93
-124.32%
16.14
Invested Capital
7.92
+7505.63%
0.10
+100.10%
-99.63
-32.30%
-75.31
Net Tangible Assets
7.92
+7505.63%
0.10
+100.10%
-99.63
-32.30%
-75.31
Tangible Book Value
7.92
+7505.63%
0.10
+100.10%
-99.63
-32.30%
-75.31
Derivative Product Liabilities
—
0.00
-100.00%
0.99
+21.33%
0.81
Interest Payable
0.03
-61.92%
0.07
0.00
—
Non Current Accrued Expenses
0.00
-100.00%
0.01
-94.80%
0.13
+50.51%
0.09
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-19.21
+12.07%
-21.84
-1.01%
-21.63
-21.53%
-17.79
Cash Flow From Continuing Operating Activities
-19.21
+12.07%
-21.84
-1.01%
-21.63
-21.53%
-17.79
Net Income From Continuing Operations
-22.23
+18.54%
-27.29
-10.27%
-24.74
-22.74%
-20.16
Other Non Cash Items
0.02
+8.63%
0.02
-57.29%
0.04
+169.39%
0.02
Stock Based Compensation
6.05
+202.97%
2.00
+371.22%
0.42
-35.25%
0.65
Operating Gains Losses
—
0.14
+69.96%
0.08
+318.22%
-0.04
Gain Loss On Investment Securities
—
0.14
+69.96%
0.08
+318.22%
-0.04
Unrealized Gain Loss On Investment Securities
0.00
-100.00%
2.19
0.00
—
Change In Working Capital
-3.05
-376.83%
1.10
-57.24%
2.57
+48.56%
1.73
Change In Prepaid Assets
0.08
+115.54%
-0.53
-16646.95%
-0.00
+87.51%
-0.03
Change In Payables And Accrued Expense
-3.24
-286.10%
1.74
-32.44%
2.58
+46.60%
1.76
Change In Accrued Expense
-2.73
-184.11%
3.24
+152.27%
1.28
+9.73%
1.17
Change In Payable
-0.51
+65.85%
-1.50
-216.24%
1.29
+120.21%
0.59
Change In Account Payable
-0.51
+65.85%
-1.50
-216.24%
1.29
+120.21%
0.59
Change In Other Working Capital
—
-0.11
—
—
Change In Other Current Assets
0.11
+200.00%
-0.11
0.00
—
Financing Cash Flow
23.72
-13.81%
27.53
+565.75%
4.13
-78.53%
19.26
Cash Flow From Continuing Financing Activities
23.72
-13.81%
27.53
+565.75%
4.13
-78.53%
19.26
Net Issuance Payments Of Debt
0.00
-100.00%
5.50
0.00
—
Issuance Of Debt
0.00
-100.00%
5.70
0.00
—
Repayment Of Debt
0.00
+100.00%
-0.20
0.00
—
Long Term Debt Issuance
0.00
-100.00%
5.50
0.00
—
Net Long Term Debt Issuance
0.00
-100.00%
5.50
0.00
—
Short Term Debt Issuance
0.00
-100.00%
0.20
0.00
—
Short Term Debt Payments
0.00
+100.00%
-0.20
0.00
—
Net Short Term Debt Issuance
0.00
0.00
0.00
—
Net Common Stock Issuance
23.99
+0.15%
23.96
0.00
—
Proceeds From Stock Option Exercised
0.03
0.00
—
—
Net Other Financing Charges
-0.30
+84.32%
-1.93
—
—
Changes In Cash
4.52
-20.50%
5.68
+132.49%
-17.49
-1296.78%
1.46
Beginning Cash Position
8.64
+192.08%
2.96
-85.53%
20.45
+7.70%
18.99
End Cash Position
13.16
+52.28%
8.64
+192.08%
2.96
-85.53%
20.45
Free Cash Flow
-19.21
+12.07%
-21.84
-1.01%
-21.63
-21.53%
-17.79
Interest Paid Supplemental Data
0.07
-0.11%
0.07
0.00
0.00
Income Tax Paid Supplemental Data
0.00
+0.00%
0.00
0.00
0.00
Change In Interest Payable
-0.07
+0.00%
-0.07
0.00
—
Common Stock Issuance
23.99
+0.15%
23.96
0.00
—
Issuance Of Capital Stock
23.99
+0.15%
23.96
+479.43%
4.13
-78.53%
19.26
Net Preferred Stock Issuance
—
0.00
-100.00%
4.13
-78.53%
19.26
Preferred Stock Issuance
—
0.00
-100.00%
4.13
-78.53%
19.26
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category